Celyad Oncology S.A.
CYAD
Rangering i aksjer
#31824
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Aksjekurs
$0.23358713
Markedsverdi
$11.04M
Endring (1 dag)
-7.56%
Endring (1 år)
-19.55%
Land
BE
Handel Celyad Oncology S.A. (CYAD)
Kategori
Healthcare
Aksjeprishistorikk for Celyad Oncology S.A. (CYAD)
Høyeste sluttskurs: $0.46 den 2026-02-01
Laveste sluttskurs: $41.26 den 2014-01-01
Laveste sluttskurs: $41.26 den 2014-01-01
Aksjeprishistorikk for Celyad Oncology S.A. fra 2014 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | 43.07% |
| 2025 | -74.06% |
| 2024 | 103.77% |
| 2023 | -54.89% |
| 2022 | -79.56% |
| 2021 | -47.44% |
| 2020 | -26.01% |
| 2019 | -45.72% |
| 2018 | -47.31% |
| 2017 | 103.78% |
| 2016 | -60.19% |
| 2015 | 14.38% |
| 2014 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $534.12 | 25.25% |
US
|
|
| $231.12 | 760.78% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $880.75 | 8.18% |
NL
|
|
| $289.51 | 1.72% |
BE
|
